EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone

Yuval Yogev iD, Zamir Shorer, Arie Koifman, Ohad Wormser, Max Drabkin iD, Daniel Halperin iD, Vadim Dolgin, Regina Proskorovski-Ohayon, Noam Hadar iD, Geula Davidov iD, Hila Nudelman, Raz Zarivach iD und 3 weitere

Proceedings of the National Academy of Sciences · 2023

DOI: 10.1073/pnas.2217831120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2023. Verfasst von Yuval Yogev und 14 weiteren Autor:innen. Beteiligte Einrichtung: The Morris Kahn Laboratory of Human Genetics at the National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer Sheva,…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Muscular Diseases. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Israel Science Foundation, Foulkes Foundation, Israel Ministry of Science, Technology and Space.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myopathy is the main adverse effect of the widely prescribed statin drug class. Statins exert their beneficial effect by inhibiting HMG CoA-reductase, the rate-controlling enzyme of the mevalonate pathway. The mechanism of statin myopathy is yet to be resolved, and its treatment is insufficient. Through homozygosity mapping and whole exome sequencing, followed by functional analysis using confocal microscopy and biochemical and biophysical methods, we demonstrate that a distinct form of human limb girdle muscular disease is caused by a pathogenic homozygous loss-of-function missense mutation in HMG CoA reductase ( HMGCR ), encoding HMG CoA-reductase . We biochemically synthesized and purified mevalonolactone, never administered to human patients before, and establish the safety of its oral administration in mice. We then show that its oral administration is effective in treating a human patient with no significant adverse effects. Furthermore, we demonstrate that oral mevalonolactone resolved statin-induced myopathy in mice. We conclude that HMGCR mutation causes a late-onset severe progressive muscular disease, which shows similar features to statin-induced myopathy. Our findings indicate that mevalonolactone is effective both in the treatment of hereditary HMGCR myopathy and in a murine model of statin myopathy. Further large clinical trials are in place to enable the clinical use of mevalonolactone both in the rare orphan disease and in the more common statin myopathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsMuscular DiseasesAnimalsHumansMiceAutoantibodiesHydroxymethylglutaryl CoA ReductasesMevalonic AcidMutation

Stichwörter der Autor:innen

HMGCRlimb girdle muscular dystrophymutationstatins

Substanzen

AutoantibodiesHMGCR protein, humanHydroxymethylglutaryl CoA ReductasesHydroxymethylglutaryl-CoA Reductase InhibitorsMevalonic AcidmevalonolactoneHmgcr protein, mouse

Autor:innen und Institutionen

  • The Morris Kahn Laboratory of Human Genetics at the National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer Sheva, 8410501 Israel.
  • Department of Pediatric Neurology, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, 8410101 Israel.
  • Genetics Institute, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, 8410101 Israel.
  • Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, 8410501 Israel.
  • National Institute for Biotechnology in the Negev and Ilse Katz Institute for Nanoscale Science and Technology, Ben-Gurion University of the Negev, Beer Sheva, 8410501 Israel.
  • Department of Radiology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 8410101 Israel.

ORCID-Profile: Yuval Yogev, Max Drabkin, Daniel Halperin, Noam Hadar, Geula Davidov, Raz Zarivach, Yonatan Perez, Ohad S Birk

Förderung

  • Israel Science Foundation
  • Foulkes Foundation
  • Israel Ministry of Science, Technology and Space

Zitieren

APA

Yogev, Y., Shorer, Z., Koifman, A., Wormser, O., Drabkin, M., Halperin, D., Dolgin, V., Proskorovski-Ohayon, R., Hadar, N., Davidov, G., Nudelman, H., Zarivach, R., Shelef, I., Perez, Y., & Birk, O. S. (2023). Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2217831120

Vancouver

Yogev Y, Shorer Z, Koifman A, Wormser O, Drabkin M, Halperin D, et al. Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone. Proceedings of the National Academy of Sciences. 2023. doi:10.1073/pnas.2217831120

BibTeX
@article{Yogev2023,
  author = {Yogev, Yuval and Shorer, Zamir and Koifman, Arie and Wormser, Ohad and Drabkin, Max and Halperin, Daniel and Dolgin, Vadim and Proskorovski-Ohayon, Regina and Hadar, Noam and Davidov, Geula and Nudelman, Hila and Zarivach, Raz and Shelef, Ilan and Perez, Yonatan and Birk, Ohad S},
  title = {Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2023},
  doi = {10.1073/pnas.2217831120}
}
Kostenlos starten →